MMAF is primarily used in the development of antibody-drug conjugates (ADCs) for targeted cancer therapy. It functions as a potent cytotoxic agent that is attached to monoclonal antibodies, which specifically bind to antigens on cancer cells. Once the ADC binds to the target cell, it is internalized, and MMAF is released, leading to cell death by inhibiting microtubule polymerization and disrupting cell division. This targeted approach minimizes damage to healthy cells, making it a promising option for treating various cancers, including hematologic malignancies and solid tumors. Its application is particularly significant in precision medicine, where it enhances the efficacy of treatments while reducing systemic toxicity.